Mason Hawkins Southeastern Asset Management
Mason Hawkins co-founded Southeastern Asset Management, adviser to the Longleaf Partners funds, and is a leading figure in absolute-value investing. The firm is known for concentrated portfolios, appraised-value analysis, and a long-term partnership culture with portfolio companies. Hawkins’s process emphasizes free cash flow, management alignment, and buying at a discount to intrinsic value.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Abbott
ABT
|
+$76.7M |
| 2 |
CNX Resources
CNX
|
+$23.4M |
| 3 |
Tencent Music
TME
|
+$21.1M |
| 4 |
Albertsons Companies
ACI
|
+$19.5M |
| 5 |
GLIBK
Liberty Capital Corp Series C GCI Group Common Stock
GLIBK
|
+$17.3M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
ACM Research
ACMR
|
+$45.5M |
| 2 |
Bio-Rad Laboratories Class A
BIO
|
+$45.4M |
| 3 |
PPLI
People Inc
PPLI
|
+$38M |
| 4 |
Rayonier
RYN
|
+$26.6M |
| 5 |
TripAdvisor
TRIP
|
+$26.5M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Consumer Discretionary | 17.36% |
| 2 | Consumer Staples | 15.04% |
| 3 | Communication Services | 14.65% |
| 4 | Real Estate | 14.41% |
| 5 | Industrials | 11.94% |
Similar funds
Mason Hawkins's Q2 2026 Portfolio in Review
As of Q2 2026, Mason Hawkins held 51 positions worth $1.92B, down 5.7% from $2.03B the previous quarter. Its ten largest holdings account for 63% of the portfolio.
Mason Hawkins withdrew a net $136M in Q2 2026, closing 4 positions and reducing 24 holdings. Its most notable exit was Bio-Rad Laboratories Class A, an estimated $45.4M position sold in full.
By sector, the portfolio is most concentrated in Consumer Discretionary at 17% of assets, down from 20% a quarter earlier, followed by Consumer Staples and Communication Services.
Against the trend, Mason Hawkins opened a new position in Abbott worth $76.3M.
- Mason Hawkins's largest Q2 2026 buy was Abbott: 840,747 shares worth $76.3M.
- Mason Hawkins added most to CNX Resources in Q2 2026, an estimated $23.4M increase.
- Mason Hawkins's biggest Q2 2026 reduction was ACM Research, cutting an estimated $45.5M.
- Mason Hawkins fully exited Bio-Rad Laboratories Class A in Q2 2026, selling an estimated $45.4M.
- Mason Hawkins's ten largest holdings make up 63% of its $1.92B portfolio in Q2 2026.
- Mason Hawkins opened 2 new positions and closed 4 in Q2 2026.
- Mason Hawkins's portfolio value fell 5.7% quarter-over-quarter to $1.92B.
Based on Southeastern Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.